Midazolam Hameln (Midazolam Hydrochloride)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This hyperpolarizes the cells, leading to reduced neuronal excitability and producing sedation, anxiolysis, anticonvulsant effects, and muscle relaxation.

The dose of Midazolam Hameln is determined by the prescribing clinician based on the indication, patient age, weight, renal and hepatic function, and the chosen route of administration. Only a qualified health professional should set the dosing regimen.

Safety data for Midazolam in pregnancy and lactation are limited. It is generally classified as a drug to be used only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Midazolam has a rapid onset of action and a relatively short duration compared with many other benzodiazepines, making it suitable for procedural sedation and induction of anesthesia. Its pharmacokinetic profile allows for quick recovery, whereas agents like diazepam have longer half‑lives and prolonged effects.

Midazolam Hameln should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture, and extreme temperature fluctuations to maintain stability.

Midazolam Hameln is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or rectally, depending on the clinical situation and the prescriber's judgment.

The most serious risks include respiratory depression, severe hypotension, paradoxical reactions such as agitation, and rare cases of anaphylaxis. Continuous monitoring of vital signs is essential during and after administration.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals who have taken large amounts of alcohol or other CNS depressants that could lead to profound sedation.